Funding for this research was provided by:
Health Research Council of New Zealand (Independent Research Organisation funding)
Text and Data Mining valid from 2018-07-13
Received: 26 April 2018
Accepted: 27 June 2018
First Online: 13 July 2018
Ethics approval and consent to participate
: Prospective ethics approval was obtained from the Health and Disability Ethics Committees, New Zealand (Reference 16/STH/13).
: Not applicable.
: GB, MW and TM have no conflicts of interest to declare. IB has conducted research funded by GSK, Astra-Zeneca and Fisher & Paykel. JF has received support to attend educational meetings from AstraZeneca, Boehringer-Ingelheim, GSK, and Novartis, has conducted research funded by GSK, Astra-Zeneca and Fisher & Paykel, and has received honoraria for speaking from AstraZeneca, Boehringer-Ingelheim and Novartis. RB has participated in advisory boards for AstraZeneca, GlaxoSmithKline and Novartis; received research grants from AstraZeneca, Cephalon, Fisher & Paykel, Genentech, GlaxoSmithKline, Novartis and Sanofi Aventis, and received payment for lectures or support to attend meetings from AstraZeneca and GlaxoSmithKline AB, RK, PB and PDY are GSK employees and hold GSK shares. KR and SJ are GSK employees.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.